Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Galera TherapeuticsGRTXD -1.02%35 Market Cap is $17.03 Mil as of Jul. 14, 2026. GuruFocus rates GRTXD with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 1,423 Biotechnology companies, Galera Therapeutics ranks worse than 78.22% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Galera Therapeutics's share price for the quarter that ended in Mar. 2026 was $9. Galera Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 0.38 Mil. Therefore, Galera Therapeutics's market cap for the quarter that ended in Mar. 2026 was $3.39 Mil.
Galera Therapeutics's quarterly market cap
increased
from Sep. 2025 ($1.33 Mil) to Dec. 2025 ($1.66 Mil) and
increased
from Dec. 2025 ($1.66 Mil) to Mar. 2026 ($3.39 Mil).
Galera Therapeutics's annual market cap
declined
from Dec. 2023 ($7.91 Mil) to Dec. 2024 ($3.45 Mil) and
declined
from Dec. 2024 ($3.45 Mil) to Dec. 2025 ($1.66 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Galera Therapeutics's Enterprise Value for Today is $13.11 Mil.
Galera Therapeutics (OTCPK:GRTXD) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Galera Therapeutics Market Cap Related Terms
Galera Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Galera Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Galera Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galera Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Galera Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Galera Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Galera Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galera Therapeutics (GRTXD) has a Market Cap of $17.03 Mil as of Jul. 14, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Galera Therapeutics and its competitors. According to the industry distribution chart, Galera Therapeutics ranks #1113 out of 1423 companies in the Biotechnology industry, placing it in the top 78.2%.
Is Galera Therapeutics' Market Cap too high?
Galera Therapeutics' current Market Cap is $17.03 Mil. The Biotechnology industry median Market Cap is 115.88. Galera Therapeutics' value of $17.03 Mil is 85.3% below this industry median. Based on the distribution chart, Galera Therapeutics ranks #1113 out of 1423 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Galera Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Galera Therapeutics' Market Cap compare to CELU and BCDA?
According to the Biotechnology industry distribution chart, Galera Therapeutics ranks #1113 out of 1423 companies for Market Cap. This places Galera Therapeutics in the lower half of its industry. The industry median Market Cap is 115.88. Galera Therapeutics' value of $17.03 Mil is 85.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 115.88, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galera Therapeutics's current Market Cap of $17.03 Mil is 85.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Galera Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 115.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galera Therapeutics's current Market Cap is $17.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galera Therapeutics stock overvalued right now?
Galera Therapeutics (GRTXD) has a current Market Cap of $17.03 Mil. The current Market Cap is $17.03 Mil and 85.3% below the Biotechnology industry median of 115.88. Galera Therapeutics' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Galera Therapeutics (GRTXD), the current Market Cap is $17.03 Mil as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galera Therapeutics Inc is a biopharmaceutical company that historically was focused on developing a portfolio of small-molecule superoxide dismutase (SOD) mimetics to improve radiotherapy in cancer, mainly by reducing one of the common side effects of radiotherapy, severe oral mucositis (SOM). Superoxide Dismutase Mimetics: excess superoxide from cancer, autoimmune diseases, or therapies like radiotherapy causes oxidative damage. Galera's SOD mimetics, avasopasem and rucosopasem, mimic natural enzymes to convert superoxide into hydrogen peroxide, reducing oxidative stress. Avasopasem is in trials for hormone-resistant advance breast cancer. Nitric oxide (NO) promotes tumor growth, angiogenesis, metastasis, and immune evasion.
35GF Score
Get the complete analysis for GRTXD
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRTXD has been successfully added to your 
